Chinese guideline for the diagnosis and treatment of drug-induced liver injury: an update.
Yimin MaoShiwu MaChenghai LiuXiaoyan LiuMinghua SuDongliang LiYiling LiGongying ChenJun ChenJinjun ChenJingmin ZhaoXiaoyan GuoJieting TangYuzheng ZhugeQing XieWen XieRongtao LaiDachuan CaiQingxian CaiYang ZhiXiaoyun Linull nullPublished in: Hepatology international (2024)
Drug-induced liver injury (DILI) is an important adverse drug reaction that can lead to acute liver failure or even death in severe cases. Currently, the diagnosis of DILI still follows the strategy of exclusion. Therefore, a detailed history taking and a thorough and careful exclusion of other potential causes of liver injury is the key to correct diagnosis. This guideline was developed based on evidence-based medicine provided by the latest research advances and aims to provide professional guidance to clinicians on how to identify suspected DILI timely and standardize the diagnosis and management in clinical practice. Based on the clinical settings in China, the guideline also specifically focused on DILI in chronic liver disease, drug-induced viral hepatitis reactivation, common causing agents of DILI (herbal and dietary supplements, anti-tuberculosis drugs, and antineoplastic drugs), and signal of DILI in clinical trials and its assessment.
Keyphrases
- drug induced
- liver injury
- adverse drug
- liver failure
- clinical trial
- clinical practice
- hepatitis b virus
- sars cov
- pulmonary embolism
- randomized controlled trial
- emergency department
- palliative care
- climate change
- pulmonary tuberculosis
- study protocol
- acute respiratory distress syndrome
- human health
- hiv aids
- open label
- double blind